Abstract: The disclosed embodiments are directed to dynamic aspect media presentations. In an embodiment, a method comprises: obtaining, by a mobile device, a first set of instructions for playing a media presentation in a first format, the media presentation including a composition of media assets; playing, by a media player of the mobile device, the media presentation in a media player view in the first format according to the first set of instructions; obtaining, by the mobile device, a switching event trigger signal; responsive to the switching event trigger signal: obtaining, by the mobile device, a second set of instructions for playing the media presentation in a second format that is different than the first format; and playing, by the media player, the media presentation in the media player view in the second format according to the second set of instructions.

Abstract: The invention relates generally to compounds of formula (I) that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Abstract: The invention relates generally to compounds that modulate the activity of TGFBETA R-1 and TGFBETA R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF? R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Abstract: A ramjet projectile comprising: an outer assembly that is tubular and comprises first, second and third portions; solid ramjet fuel attached to and disposed inside the first portion of the outer assembly; an inner assembly disposed inside the outer assembly and comprising a first portion threadably coupled to the second portion of the outer assembly and a second portion surrounded by the third portion of the outer assembly to form an annular air passageway having an air inlet. The first portion of the inner assembly comprising a plurality of openings spatially distributed about a circumference. The inner assembly is rotatable relative to the outer assembly between first and second locations displaced by a distance from each other during travel along the gun barrel. The openings are not in flow communication with the annular air passageway when the inner assembly is at the first location and are in flow communication with the annular air passageway when the inner assembly is at the second location.

Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Abstract: Roughly described, individuals in both a training system and in a production system include a label field in their rule outputs. Positions entered by an individual are maintained in a status record for the individual, including the label output by the rule which triggered entry of that position. Rules that assert exiting or partial exiting of a position also output the label from the rule which triggered the assertion, and are effective only so far as matching positions exist or remain in the individual's status record, including a matching label. Labels present in the status record also can be referenced in conditions of a rule. During evolution, a rule's output label is subject to crossover and/or mutation just like the conditions and output assertions.

Abstract: Some embodiments provide a method for creating a composite presentation. In some embodiments, this method is performed by an application that executes on a computing device that stores media content pieces (e.g., videos, still images, etc.), and/or that has access through a network to media content pieces (MCPs) stored on other computing devices. The method of some embodiments (1) performs a first automated process that analyzes the MCPs (e.g., analyzes the content and/or metadata of the MCPs) to define one or more MCP groups, (2) based on one or more compositing parameters, performs a second automated process to generate composite presentation definitions from the defined MCP groups, and (3) produces a user interface (UI) layout that identifies the defined composite presentations and provides tools for adjusting the compositing parameters to adjust the defined composite presentations.

Abstract: Some embodiments provide a method for creating a composite presentation. The method performs a first automated process to select a subset of media content pieces from a set of available media content pieces (MCPs), based on analysis of metadata associated with the MCPs. The method performs a second automated process to generate a definition of the composite presentation from the selected subset of MCPs. The second automated process defines edits that select desired portions of the selected subset of MCPs for inclusion in the composite presentation. The method then renders the composite presentation based on the generated definition.

Abstract: Some embodiments provide a media compositing method that performs automated processes (1) to analyze the media content pieces (MCPs) to define one or more MCP groups, and (2) produces a user interface (UI) layout that identifies the defined MCP groups as groups for which the method can display composite presentations (e.g., video presentations). To define the MCP groups, the method of some embodiments uses one or more media grouping templates (MGTs). In some embodiments, the method can define multiple MGT instances for an MGT. For instance, in some embodiments, the MGTs include (1) location-bounded MGTs (e.g., videos and/or photos captured within a region with a particular radius), (2) time-bounded MGTs (e.g., videos and/or photos captured within a particular time range and/or date range), (3) time-bounded and location-bounded MGTs (e.g., mornings at a beach), (4) content-defined MGTs (e.g., videos and/or photos containing smiles), and (5) user-metadata based MGTs (e.g.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: A supersonic inlet includes a supersonic section including a cowl which is at least partially elliptical, a ramp disposed within the cowl, and a flow inlet disposed between the cowl and the ramp. The ramp may also be at least partially elliptical.

Abstract: Disclosed are compounds of Formula (I): (Formula (I)) wherein: R1 is —CH2CH2CF3; R2 is —CH2CH2CH2F, —CH2CF2CH3, —CH2CH2CF3, —CH2CH(CH3)CF3, —CH2CH2CF2CH3, (Formulae (II), (III), (IV), (V) or (VI): R3 is H or —CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.

Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: Disclosed are compounds of Formula (I) and/or salts thereof: wherein R1 is —CH2CH2CF3; R2 is —CH2CH2CF3 or —CH2CH2CH2CF3; R3 is H, —CH3, or Rx; R4 is H or Ry; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer; or as prodrugs of such compounds.

Abstract: Disclosed are compounds of Formula (I) and salts thereof, wherein: a) R1 is H or CH3, and R2 is Ry; or b) R1 is Rx and R2 is H; wherein Rx and Ry are disclosed herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are prodrugs of compounds that are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.